Zenas Biopharma IncNASDAQ:ZBIO
- LAST PRICE19.5000
- TODAY'S CHANGE (%)0.5000 (2.6316%)
- Bid / Lots19.4900/ 2
- Ask / Lots19.9100/ 4
- Open / Previous Close19.4000 / 19.0000
- Day Range
- 52 Week Range
- Volume39,046
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ZBIO |
|---|---|---|
| 09:32 ET | 3061 | 19.4 |
| 09:34 ET | 715 | 19.705 |
| 09:36 ET | 3454 | 19.89 |
| 09:38 ET | 9155 | 19.6523 |
| 09:39 ET | 3800 | 19.42 |
| 09:41 ET | 8717 | 19.23 |
| 09:43 ET | 4511 | 19.28 |
| 09:45 ET | 400 | 19.3 |
| 09:56 ET | 860 | 19.5 |
| 09:57 ET | 550 | 19.4206 |
| 09:59 ET | 300 | 19.4 |
| 10:10 ET | 100 | 19.49 |
| 10:14 ET | 200 | 19.5 |
Sep 19, 2024
Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering, from 4:15PM ET on Thursday Sep 19, 2024 by Dow Jones
4:15PM ET on Thursday Sep 19, 2024 by Dow JonesZenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering, from 4:15PM ET on Thursday Sep 19, 2024 by Dow Jones
4:15PM ET on Thursday Sep 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Zenas Biopharma Inc | 756.1M | -14.2x | --- |
Abcellera Biologics Inc | 763.2M | -4.9x | --- |
CureVac NV | 724.5M | -2.3x | --- |
Exscientia PLC | 651.4M | -3.7x | --- |
Arbutus Biopharma Corp | 758.9M | -9.2x | --- |
Tango Therapeutics Inc | 889.3M | -7.2x | --- |
Company Information
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on the development and commercialization of immunology-based therapies for patients in need. Its lead immunology and inflammation (I&I) product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. It is developing obexelimab as a potential I&I franchise for patients in several autoimmune diseases. Its pipeline also includes two global programs, ZB002 (an anti-TNFα monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion), and two regional programs, ZB001 (also known as VRDN-001, an IGF-1R monoclonal antibody), and related programs, and ZB005 (also known as DNTH103, an anti-active C1s monoclonal antibody), for which the Company hold the development and commercialization rights in greater China.
Contact Information
- Headquarters
- 1000 Winter St, Suite 1200WALTHAM, MA, United States 02451
- Phone
- 857-271-2954
- Fax
- 302-655-5049
Executives
- Founder, Chairman of the Board of Director, Chief Executive Officer
- Leon Moulder
- President, Chief Operating Officer
- Joseph Farmer
- Chief Business Officer and Chief Financial Officer
- Jennifer Fox
- Chief Commercial Officer
- Orlando Oliveira
- Independent Director
- Patricia Allen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $756.1M |
|---|---|
Revenue (TTM) | $50.0M |
Shares Outstanding | 39.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.38 |
Book Value | $0.61 |
P/E Ratio | -14.2x |
Price/Sales (TTM) | 15.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -112.87% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
